Log In
BCIQ
Print this Print this
 

VT-122PC

  Manage Alerts
Collapse Summary General Information
Company Vicus Therapeutics LLC
DescriptionFixed-dose combination of propranolol, a non-selective adrenergic receptor beta (ADRB) blocker, and etodolac, a cyclooxygenase-2 (COX-2) inhibitor
Molecular Target Adrenergic receptor beta (ADRB) ; Cyclooxygenase-2 (COX-2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard Indication Inflammation (unspecified)
Indication DetailsTreat cancer-induced systemic inflammation and cachexia in patients with advanced pancreatic cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today